Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

doi:10.1186/s12916-017-0949-7

CORC > 武汉物理与数学研究所 > 中国科学院武汉物理与数学研究所 > 磁共振应用研究部

	Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
	Steenholdt, Casper 4; Bjerrum, Jacob Tveiten 4; Wang, Yulan 2,3; Hao, Fuhua 3; Gunther, Ulrich Leonhard 1; Atkins, Karen 1; Reed, Michelle A. C.1; Nielsen, Ole Haagen 4; Ainsworth, Mark 4
刊名	BMC MEDICINE
	2017-10-16
卷号	15
关键词	Crohn's Disease Diagnostics Metabolomics Serum Ulcerative Colitis
DOI	10.1186/s12916-017-0949-7
文献子类	Article
英文摘要	Background: One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great clinical significance. This study employs spectroscopy- based metabolic profiling of serum from patients with IBD treated with IFX and healthy subjects (1) to substantiate the use of spectroscopy as a semi-invasive diagnostic tool, (2) to identify potential biomarkers of treatment response and (3) to characterise the metabolic changes during management of patients with tumour necrosis factor-alpha inhibitors.
WOS关键词	CROHNS-DISEASE ; ULCERATIVE-COLITIS ; DOSE INTENSIFICATION ; RISK-FACTORS ; TNF-ALPHA ; IBD ; SPECTROSCOPY ; BIOMARKER ; SERUM ; PLS
WOS研究方向	General & Internal Medicine
语种	英语
WOS记录号	WOS:000412907300001
资助机构	European Union(FP7-INFRA-2010-1.1.8-261863 Bio-NMR) ; European Union(FP7-INFRA-2010-1.1.8-261863 Bio-NMR) ; COSMOS EU(FP7-INFRA-2012-1-312941) ; COSMOS EU(FP7-INFRA-2012-1-312941) ; European Union(FP7-INFRA-2010-1.1.8-261863 Bio-NMR) ; European Union(FP7-INFRA-2010-1.1.8-261863 Bio-NMR) ; COSMOS EU(FP7-INFRA-2012-1-312941) ; COSMOS EU(FP7-INFRA-2012-1-312941)
内容类型	期刊论文
源URL	[http://ir.wipm.ac.cn/handle/112942/11422]
专题	武汉物理与数学研究所_磁共振应用研究部
作者单位	1.Univ Birmingham, Inst Canc & Genom Sci, HWB NMR, Birmingham, W Midlands, England 2.Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China 3.Chinese Acad Sci, State Key Lab Magnet Resonance & Atom & Mol Phys, Key Lab Magnet Resonance Biol Syst, Wuhan Ctr Magnet Resonance,Wuhan Inst Phys & Math, Wuhan, Hubei, Peoples R China 4.Univ Copenhagen, Herlev Hosp, Med Sect, Dept Gastroenterol, Herlev Ringvej 75, DK-75 Herlev, Denmark
推荐引用方式 GB/T 7714	Steenholdt, Casper,Bjerrum, Jacob Tveiten,Wang, Yulan,et al. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease[J]. BMC MEDICINE,2017,15.
APA	Steenholdt, Casper.,Bjerrum, Jacob Tveiten.,Wang, Yulan.,Hao, Fuhua.,Gunther, Ulrich Leonhard.,...&Ainsworth, Mark.(2017).Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.BMC MEDICINE,15.
MLA	Steenholdt, Casper,et al."Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease".BMC MEDICINE 15(2017).